Another humanized monoclonal antibody RG7356, in development by Roche

Another humanized monoclonal antibody RG7356, in development by Roche

Roche are developing RG7356, which targets CD44, a surface receptor that is over-expressed in ZAP-70 positive CLL patients as well as some solid tumours. If early phase clinical trials proceed and show promise, this could be good news for ZAP-70 positive patients, given the generally poorer prognosis associated with this marker.

The full paper is available from the on-line edition of the Proceedings of the National Academy of Sciences:

pnas.org/content/110/15/612...

Neil

Last edited by
oldestnewest

You may also like...